Core Viewpoint - WuXi AppTec has raised its revenue forecast for 2025 for the third time, indicating strong growth potential in its business operations [1] Group 1: Revenue Forecast - The company expects to achieve approximately 45.456 billion yuan in revenue for 2025, representing a year-on-year growth of about 15.84% [1] - Revenue from continuing operations is projected to grow by approximately 21.40% year-on-year [1] - The previous revenue forecast was adjusted from a range of 42.5 billion to 43.5 billion yuan to a new range of 43.5 billion to 44 billion yuan [1] Group 2: Profitability - The company anticipates a net profit attributable to shareholders of approximately 19.151 billion yuan for 2025, reflecting a year-on-year increase of about 102.65% [1] - This net profit is expected to set a new historical high for the company [1]

Core Viewpoint - WuXi AppTec (603259.SH, 02359.HK) has raised its revenue forecast for 2025 for the third time, expecting approximately 45.456 billion yuan in revenue, a year-on-year increase of about 15.84%, with a significant net profit forecast of around 19.151 billion yuan, representing a 102.65% increase year-on-year, marking a historical high for the company [1][3]. Group 1 - The company expects 2025 revenue to reach approximately 45.456 billion yuan, with a year-on-year growth of about 15.84%, and a 21.40% increase in revenue from continuing operations [1]. - The previous revenue forecast was adjusted from 42.5-43.5 billion yuan to 43.5-44 billion yuan during the Q3 report [1]. - The anticipated net profit for 2025 is approximately 19.151 billion yuan, which is a historical high and represents a year-on-year increase of about 102.65% [1][3]. Group 2 - The company focuses on a unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, enhancing production efficiency and expanding capabilities to drive steady business growth [3]. - Significant net profit contributions are expected from the sale of assets, including approximately 4.161 billion yuan from the sale of shares in WuXi AppTec's subsidiary and about 1.434 billion yuan from the sale of 100% equity in two clinical research companies, totaling nearly 5.6 billion yuan in net gains [3]. - The asset sales align with the company's strategy to focus on the CRDMO business model, providing funding support for global capacity expansion [3].

Core Viewpoint - WuXi AppTec (药明康德) anticipates an increase in revenue and net profit for the fiscal year ending December 31, 2025, compared to the same period in 2024, driven by its integrated CRDMO business model and strategic asset sales [1][2]. Group 1: Financial Performance - The company expects to achieve revenue of approximately RMB 45,456.17 million, representing a year-on-year growth of about 15.84%, with a 21.40% increase in revenue from continuing operations [1]. - Adjusted net profit attributable to shareholders is projected to be around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be about RMB 13.241 billion, with a year-on-year increase of approximately 32.56% [1]. - The total net profit attributable to shareholders is anticipated to be around RMB 19.151 billion, showing a significant year-on-year growth of approximately 102.65% [1]. - Basic earnings per share are expected to be approximately RMB 6.70, representing a year-on-year increase of about 104.27% [1]. Group 2: Business Strategy and Operations - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, enhancing capabilities and building new production capacity to meet customer demands [2]. - The impact of non-recurring gains on net profit primarily stems from the sale of a portion of its stake in WuXi XDC Cayman Inc., expected to yield a net gain of approximately RMB 4.161 billion, and the sale of 100% stakes in Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd., expected to yield a net gain of approximately RMB 1.434 billion [2].

Core Viewpoint - WuXi AppTec is expected to achieve significant revenue and profit growth in 2025, driven by its core business operations and strategic asset sales [1] Financial Performance - The company anticipates total revenue of approximately RMB 45.46 billion for 2025, representing a year-on-year increase of about 15.8% [1] - Revenue from continuing operations is projected to grow by approximately 21.4% year-on-year [1] - The expected net profit attributable to shareholders is around RMB 19.15 billion, reflecting a substantial year-on-year growth of approximately 102.6% [1] - The basic earnings per share for 2025 is estimated to be about RMB 6.70, which indicates a year-on-year increase of approximately 104.3% [1]

智通财经APP获悉，1月12日晚间，药明康德(603259.SH/02359)披露了其2025年度预增公告。公告显示，公司预计全年营业收入约456.56亿元，同比增长约 15.84%；其中持续经营业务收入同比增长约21.4%。盈利方面，经调整non-IFRS归母净利润、归母净利润、扣非归母净利润分别同比增长约41.33%、 102.65%及32.56%，基本每股收益同样翻倍达到6.7元。 在归母净利润、每股收益达成新高的背景下，药明康德2025年度现金分红亦有望创下新高。按照此前，公司在三季度业绩交流会上曾表示，上市以来一贯维 持约30%的现金分红比例。根据本次预告的归母净利润测算，2025年度现金分红总额预计将突破57亿元。 根据统计，上市以来的七年时间里，药明康德通过现金分红、回购及注销股份的方式，累计回馈投资者达到200亿元，超过了公司过去七年累计净利润的 40%。 ...

智通财经APP获悉，2026年1月12日晚间，药明康德(603259.SH/02359)发布了2025年度业绩预增公告。公司预计2025年全年营业收入约454.56亿元，创下历 史新高。 除了创记录的营业收入，药明康德的利润层面，三个口径下关键指标亦实现高于营收的增速攀升，经调整non-IFRS归母净利润、归母净利润及扣非后归母净 利润，分别同比增长约41.33%、102.65%及32.56%。 此前，药明康德已在三季度时第二次上调了全年经营目标。公司表示，紧抓客户需求、业务模式和管理执行的确定性，进一步上调全年业绩指引，预计2025 年持续经营业务重回双位数增长，增速上调至17~18%，公司整体收入上调至435~440亿元。 ...

Core Viewpoint - WuXi AppTec has reported record-high revenue and profit figures for the fiscal year 2025, indicating strong financial performance and commitment to shareholder value through significant cash dividends [1] Financial Performance - The company announced that its revenue and profit metrics have reached historical highs, with basic earnings per share doubling to 6.70 yuan per share [1] - The expected net profit attributable to shareholders for 2025 is projected to exceed 57 billion yuan, leading to record cash dividends for shareholders [1] Shareholder Value - WuXi AppTec has maintained a leading cash dividend payout ratio of 30% since its listing, reflecting its commitment to returning value to shareholders [1] - The company plans to unlock a total of 2.5 billion Hong Kong dollars in H-share incentives, contingent upon achieving specific revenue targets [1] Incentive Plans - The core unlocking conditions for the 2025 H-share incentive trust plan have been met, with revenue targets set at 42 billion yuan and 43 billion yuan for additional stock grants [1] - The incentive plan aims to foster long-term development and alignment of interests between core talent and the company [1]

根据统计，上市以来的七年时间里，药明康德通过现金分红、回购及注销股份的方式，累计回馈投资者 达到200亿元，超过了公司过去七年累计净利润的40%。 在归母净利润、每股收益达成新高的背景下，药明康德2025年度现金分红亦有望创下新高。按照此前， 公司在三季度业绩交流会上曾表示，上市以来一贯维持约30%的现金分红比例。根据本次预告的归母净 利润测算，2025年度现金分红总额预计将突破57亿元。 智通财经APP获悉，1月12日晚间，药明康德(603259.SH/02359)披露了其2025年度预增公告。公告显 示，公司预计全年营业收入约456.56亿元，同比增长约15.84%；其中持续经营业务收入同比增长约 21.4%。盈利方面，经调整non-IFRS归母净利润、归母净利润、扣非归母净利润分别同比增长约 41.33%、102.65%及32.56%，基本每股收益同样翻倍达到6.7元。 ...

Group 1 - The core viewpoint of the article is that WuXi AppTec (603259.SH/02359) has announced a significant increase in its revenue forecast for the year 2025, projecting approximately 45.456 billion yuan, marking a historical high [1] - The company has raised its annual performance guidance for the second time in the third quarter, indicating a strong focus on customer demand, business model, and management execution certainty [1] - WuXi AppTec expects its continuous operating business to return to double-digit growth, with an adjusted growth rate of 17-18%, and overall revenue revised to 43.5-44 billion yuan [1] Group 2 - In terms of profitability, key indicators under three metrics are expected to grow at a rate higher than revenue, with adjusted non-IFRS net profit, net profit attributable to shareholders, and net profit attributable to shareholders after deducting non-recurring gains and losses projected to increase by approximately 41.33%, 102.65%, and 32.56% year-on-year, respectively [1]

Core Viewpoint - WuXi AppTec has reported record-high revenue and profit figures for the fiscal year 2025, with basic earnings per share doubling to 6.70 CNY per share [1] Group 1: Financial Performance - The company achieved historical highs in revenue and profit across three metrics for the fiscal year 2025 [1] - The expected net profit attributable to shareholders for 2025 is projected to lead to a record cash dividend of over 5.7 billion CNY [1] Group 2: Shareholder Returns - WuXi AppTec has maintained a leading cash dividend ratio of 30% since its listing, reflecting its commitment to returning value to shareholders [1] - The anticipated rapid growth in net profit will be shared with shareholders through cash dividends [1] Group 3: Incentive Plans - The company has met the core unlocking conditions for its 2025 H-share incentive trust plan, with revenue targets set at 42 billion CNY and 43 billion CNY for additional stock grants [1] - A total of 2.5 billion HKD in equity incentives is set to be unlocked, aimed at fostering long-term development with core talent [1]